Xalud Therapeutics
Manufacturing · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
40 W 57th St Ste 1810, New York, New Yor...Phone Number
(212) 301-6673Website
www.xaludthera.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Xalud Therapeutics
Founded in 2009, Xalud Therapeutics is a biotechnology company developing a non-viral gene therapy platform to treat pathologic inflammation through immune modulation. Xalud Therapeutics is located in New York.Explore more
Xalud Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Xalud Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Xalud Therapeutics recently announced quarterly report
Check out if Xalud Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Xalud Therapeutics has new funding data
Xalud Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Xalud Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Xalud Therapeutics
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Xalud Therapeutics launches new products
Click to see if Xalud Therapeutics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Xalud Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Xalud Therapeutics
Compare insights from companies similar to Xalud Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Xalud Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Xalud Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Xalud Therapeutics.
Xalud Therapeutics financials insights
Gather financial insights about Xalud Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Unspecified
$7.3M
2020
Unspecified
$5M
2021
Series C
$30M
Xalud Therapeutics Tech Stack
A closer look at the technologies used by Xalud Therapeutics
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
New Hire
Executive Move
Funding
Xalud Therapeutics News & Media
Xalud Therapeutics Doses First Patient in Phase 2a Trial of XT-150 for the Treatment of Facet Joint Osteoarthritis Pain
NEW YORK--(BUSINESS WIRE)--Xalud Therapeutics, a clinical-stage biotechnology company developing DNA-delivered therapeutics, today announced the first patient dosed in a Phase 2a clinical trial of its lead product candidate, XT-150, for the treatment of facet joint osteoarthritis (FJOA) pain. XT-150 is a locally-injectable plasmid DNA gene therapy expressing IL-10v, a proprietary modified variant of human interleukin-10 (IL-10). XT-150 is currently being evaluated in additional clinical trialsXalud Therapeutics Receives FDA Fast Track Designation for XT-150 for the Treatment of Pain Associated with Osteoarthritis of the Knee
NEW YORK--(BUSINESS WIRE)--Xalud Therapeutics, a clinical-stage biotechnology company developing DNA delivery therapies using a non-viral platform, announced today that the United States Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead candidate, XT-150, for the treatment of pain associated with osteoarthritis of the knee. XT-150 is a locally injectable non-viral therapy expressing IL-10v, a proprietary modified variant of IL-10, that addresses patholoXalud Therapeutics Appoints Charles Triano as Chief Financial Officer
NEW YORK--(BUSINESS WIRE)--Xalud Therapeutics, a clinical-stage biotechnology company developing non-viral gene therapies to treat pathologic inflammation through immune modulation, today announced the appointment of Charles Triano as its chief financial officer. Mr. Triano brings nearly 35 years of industry experience with deep ties in the global investment community. “Chuck brings a strong reputation with an invaluable skillset and perspective to the Xalud leadership team given his broad expeXalud Therapeutics Completes Oversubscribed $30 Million Series C Financing
NEW YORK--(BUSINESS WIRE)--Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing. “We are well positioned to continue advancing XT-150, our lead therapeutic candidate, through clinical development and further expand our platform,” said Diem Nguyen, Ph.D., chief executive officer of Xalud Therapeutics. “There are over 300 million people worldwide
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Xalud Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2009, Xalud Therapeutics is a biotechnology company developing a non-viral gene therapy platform to treat pathologic inflammation through immune modulation. Xalud Therapeutics is located in New York.... Read More
